Literature DB >> 26648645

Ofatumumab.

.   

Abstract

Entities:  

Year:  2015        PMID： 26648645      PMCID： PMC4653973          DOI： 10.18773/austprescr.2015.052

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

2.  Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

Authors:  Bertrand Coiffier; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Fredriksen; Marinus H J van Oers; James Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Mimi Flensburg; Jørgen Petersen; Tadeusz Robak
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.